Skip Navigation



Annals of Oncology Advance Access published online on March 3, 2005
Annals of Oncology, doi:10.1093/annonc/mdi129
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/4/538    most recent
mdi129v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Giaccone, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giaccone, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received July 19, 2004
Revised October 26, 2004
Accepted November 30, 2004

Review

HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy

G. Giaccone 1*

1 Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

* To whom correspondence should be addressed.
G. Giaccone, E-mail: g.giaccone{at}vumc.nl


  Abstract

Therapeutic agents that target the epidermal growth factor receptor (HER1/EGFR) signal pathway, such as small-molecule tyrosine kinase inhibitors and monoclonal antibodies are now advanced in clinical development and two are already licensed for use. Complete/ongoing phase II studies with these agents clearly demonstrate that a small, but significant proportion of patients respond to HER1/EGFR inhibition. However, with our current understanding of tumour biology and genetics, we cannot explain why some patients respond well and others less so or not at all. These differences may be a result of many factors, such as patients' genotype and phenotype, pharmacological and pharmacokinetic differences between agents or the inherent molecular heterogeneity of tumours. In this article, we explore current strategies to identify patients who respond differently and ways to maximise the clinical benefit of these therapies. This includes defining optimal dose and dosing schedules, identifying appropriate combination partners and finding predictive and surrogate markers of response. The association between HER1/EGFR gene mutations in non-small cell lung cancer (NSCLC) tumours and response to HER1/EGFR-targeted agents is also discussed. This may help us to preselect responsive patients, tailor the dose according to the individual's tolerability, or monitor these agents to optimise/interrupt therapy at an early stage.

Keywords: HER1/EGFR; Iressa; predictive marker; surrogate market; Tarceva; tyrosine kinase inhibitor.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
S. D. RICE, J. E. BUSH, and S. L. BROWER
Assessment of Erlotinib in Chemoresponse Assay
Anticancer Res, June 1, 2009; 29(6): 1993 - 1997.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Eberhard, G. Giaccone, and B. E. Johnson
Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting
J. Clin. Oncol., February 20, 2008; 26(6): 983 - 994.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. Toschi and F. Cappuzzo
Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Oncologist, February 1, 2007; 12(2): 211 - 220.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. S. Siegel-Lakhai, J. H. Beijnen, and J. H.M. Schellens
Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva(R)) and Gefitinib (Iressa(R))
Oncologist, September 1, 2005; 10(8): 579 - 589.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.